Back to Journals » OncoTargets and Therapy » Volume 7

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

Authors Vyas D, Laput G, Vyas A

Received 4 January 2014

Accepted for publication 7 February 2014

Published 12 June 2014 Volume 2014:7 Pages 1015—1023

DOI https://doi.org/10.2147/OTT.S60114

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Dinesh Vyas, Gieric Laput, Arpitak K Vyas

College of Human Medicine, Michigan State University, East Lansing, MI, USA

Abstract: The lack of therapy and the failure of existing therapy has been a challenge for clinicians in treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line therapy in various cancers; however, toxicity, resistance, and treatment failure limit their clinical use. Their status leads us to discover and investigate more targeted therapy with more efficacy. In this article, we dissect literature from the patient perspective, the tumor biology perspective, therapy-induced metastasis, and cell data generated in the laboratory.

Keywords: chemotherapy, cancer, inflammation


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]